Exact Sciences’ (NDAQ: EXAS) history is a tale of two halves. Founded in 1995 in Marlborough, Massachusetts, “Exact,” as the company is known, went public in 2001 but struggled to find its footing, ...

The rumors are now a reality. Abbott Laboratories is acquiring Exact Sciences for $21 billion, marking what could be the biggest medtech deal of 2025. The deal’s announcement comes less than 24 hours ...

Exact Sciences has moved to acquire Genomic Health, with plans to bring their cancer screening and diagnostic tests up through a combined commercial organization of about 1,000 employees, including ...

How often have you heard, “Use broad match along with smart bidding to get the best results?” Broad match can learn based on previous conversion activity. It can also use previous user search data, ...

Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) fell 5.9% in the morning session after the company reported underwhelming fourth-quarter 2024 results as profit margins worsened ...

Shares of Exact Sciences (EXAS) continued to rise in the premarket on Thursday, adding ~18% after the cancer test maker agreed to be acquired by Abbott Laboratories (ABT) in an all-cash deal worth ...

The healthcare conglomerate Abbott Laboratories said on Thursday it would buy Exact Sciences, makers of the at-home colon cancer test Cologuard, for roughly $21 billion. The deal appears to be the ...

Exact Sciences is adding early cancer detection to its pipeline through its buyout of Thrive Earlier Detection for up to $2.15 billion in cash and stock. The deal comes just three months after Thrive ...

If you have been wondering whether Exact Sciences is still worth buying after its huge run, you are not alone. This breakdown is designed to help you decide if the current price makes sense. The stock ...